PharmacoEconomics
Công bố khoa học tiêu biểu
* Dữ liệu chỉ mang tính chất tham khảo
Sắp xếp:
An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis
PharmacoEconomics - Tập 37 - Trang 631-643 - 2019
This paper provides an educational review covering the consideration of costs for cost-effectiveness analysis (CEA), summarising relevant methods and research from the published literature. Cost data are typically generated by applying appropriate unit costs to healthcare resource-use data for patients. Trial-based evaluations and decision analytic modelling represent the two main vehicles for CEA...... hiện toàn bộ
Economic Evaluation of Enoxaparin Sodium versus Heparin in Unstable Angina
PharmacoEconomics - Tập 18 - Trang 83-89 - 2012
Objectives: To perform an evaluation from the societal perspective of the cost of treatment with enoxaparin sodium versus unfractionated heparin (UFH) in patients with unstable angina and non-Q wave myocardial infarction in France.
Design: Four complementary cost-minimisation analyses based on the results of the Efficacy and Safety of Subcutaneous Enoxaparin in No...... hiện toàn bộ
Cost-Effectiveness Analyses of Vaccination Programmes
PharmacoEconomics - Tập 26 - Trang 191-215 - 2012
Cost effectiveness is becoming an increasingly important factor for stakeholders faced with decisions about adding a new vaccine into national immunization programmes versus alternative use of resources. Evaluating cost effectiveness, taking into account the relevant biological, clinical, epidemiological and economic factors of a vaccination programme, generally requires use of a model. This revie...... hiện toàn bộ
Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer’s Disease Interventions
PharmacoEconomics - Tập 37 - Trang 597-608 - 2019
Alzheimer’s disease or dementia can impose a significant burden on family and other informal caregivers. This study investigated how the inclusion of family/informal caregiver spillover effects in a cost-utility analysis may influence the reported value of Alzheimer’s disease/dementia interventions. We used PubMed to identify Alzheimer’s disease or dementia cost-utility analyses published from 1 J...... hiện toàn bộ
Costs for Acute Myocardial Infarction in a Tertiary Care Centre and Nationwide in France
PharmacoEconomics - Tập 17 - Trang 603-609 - 2012
Objective: We compared the estimated costs of coronary interventions from our hospital’s cost accounting system with data from the French Diagnosis Related Group (DRG) cost database, taking the perspective of our hospital.
Design: Cost data on hospital resources used by patients hospitalised for acute myocardial infarction (MI), with and without complications, inc...... hiện toàn bộ
Heath State Utility Values for Cost-Effectiveness Models
PharmacoEconomics - Tập 35 - Trang 1-3 - 2017
Macrovascular Risk Equations Based on the CANVAS Program
PharmacoEconomics - Tập 39 - Trang 447-461 - 2021
Widely used risk equations for cardiovascular outcomes for individuals with type 2 diabetes mellitus (T2DM) have been incapable of predicting cardioprotective effects observed in recent cardiovascular outcomes trials (CVOTs) involving individuals with T2DM at high risk for or with established cardiovascular disease (CVD). We developed cardiovascular and mortality risk equations using patient-level...... hiện toàn bộ
Pharmacoeconomic Evaluation in Ireland
PharmacoEconomics - Tập 28 - Trang 307-322 - 2012
Objective: To describe the pharmacoeconomic assessment process in Ireland and to provide examples of recent appraisals and the subsequent impact on pricing and reimbursement decisions.
Method: The pharmacoeconomic appraisals conducted by the National Centre for Pharmacoeconomics (NCPE) between September 2006 and February 2009 were reviewed. The NCPE recommendation...... hiện toàn bộ
Tổng số: 2,573
- 1
- 2
- 3
- 4
- 5
- 6
- 10